Search Results

Showing results 21-30 of 30 for 'Clinical trials'


  • eye-image-tn
    Using Young Cells to Fight Age-Related Macular Degeneration

    Israeli company Cell Cure Neurosciences is conducting clinical trials on a stem-cell-based treatment for age-related macular degeneration (AMD), reports Israel21c. The firm's CEO, Charles Irving, conducted his doctoral research in chemistry at Weizmann. Currently, treatment options for AMD – a major cause of blindness in adults – are limited.

    /news-media/in-the-news/using-young-cells-to-fight-age-related-macular-degeneration
  • Blood-Test-for-Alzheimers-thumb
    Blood Test for Alzheimer's

    Twenty years of research by the Institute's Prof. Michal Schwartz has resulted in a blood test for Alzheimer's disease that is now the focus of a startup venture with U.S. collaborators. As Israel21c reports, the first human trials by the new company, NeuroQuest, show that the test is 87% accurate for Alzheimer's and ALS.

    /news-media/in-the-news/blood-test-for-alzheimers
  • dementia-tn
    Brain’s Immune System ""Key to Reversing Dementia""

    ""Alzheimer's disease could be halted and even reversed by altering the brain's immune system,"" says the U.K.'s Express. The paper reports on the groundbreaking research of Prof. Michal Schwartz, which combines neuroscience and immunology to give us new understanding of the brain and its diseases – and novel ways to treat those diseases.

    /news-media/in-the-news/brain8217s-immune-system-key-to-reversing-dementia
  • steba-research-tn
    Steba Offers Prostate Cancer Patients a Better Approach

    It takes a village to bring a new treatment to market – and in the case of the prostate cancer therapy developed by Profs. Avigdor Scherz and Yoram Salomon, that village includes Steba Biotech, which said ""We looked at the technology for ten minutes and said, ‘We'll take it'."" Globes interviews the father and son behind the Israel-based pharmaceutical house.

    /news-media/in-the-news/steba-offers-prostate-cancer-patients-a-better-approach
  • flu-vaccine-tn
    Israel's Universal Flu Vaccine Heads for Universal Acceptance

    Weizmann Institute research that led to a ""universal"" flu vaccine – meaning it works against all forms of influenza – has now been granted patents by the European Union and Japan. The vaccine was developed by an Israeli firm, BiondVax, which is now preparing to license it to governments and pharma companies. Before this breakthrough, scientists developed vaccines to fight each strain of flu.

    /news-media/in-the-news/israels-universal-flu-vaccine-heads-for-universal-acceptance
  • schwartz-michal-tnfbdf88dac497647cb66dff00005fc039
    NeuroQuest to Begin US Clinical Validation Trials for Alzheimer's Blood Test

    A blood test for early detection of Alzheimer's disease, based on Prof. Michal Schwartz's research, exceeded Alzheimer's Association standards in recent trials. Now, NeuroQuest, the firm behind the test, has announced it will be working with UC San Diego on clinical validation. The test may be able to identify the disease many years earlier.

    /news-media/in-the-news/neuroquest-to-begin-us-clinical-validation-trials-for-alzheimers-blood-test
  • tookad-doctors-tn
    Israel Leads in Prostate Cancer Research

    Reporter Natasha Kirtchuk describes the new prostate cancer treatment developed by the Weizmann Institute's Profs. Avigdor Scherz and Yoram Salomon, along with an extended team of scientists, researchers, oncologists, urologists, clinicians, technicians, and more. The therapy involves no radiation or chemotherapy, takes just 90 minutes to complete...

    /news-media/video-gallery/israel-leads-in-prostate-cancer-research
  • 2016-09-acwis-enews-thumbnail
  • c26_HA800[1].jpg
    EMA Approves Steba’s Prostate Cancer Drug

    The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended by a majority of 29-2 the approval for marketing of the Tookad drug for treatment of prostate cancer developed by Israeli company Steba Biotech. Tookad is a complex treatment, in which the patient takes a drug, but the drug is activated only in the area of the tumor, through the skin. The product, developed by Professor Avigdor Scherz and Dr. Yoram Salomon of the Weizmann Institute of Science, has already been approved for marketing and sale in Israel and Mexico.

    /news-media/in-the-news/ema-approves-steba-s-prostate-cancer-drug
  • 393777.jpg
    Can the Organ of Life Save Lives?

    As <em>The Jerusalem Post</em> reports, Pluristem uses technology developed by Weizmann and the Technion to develop cell therapies for conditions such as inflammation, muscle injuries, blood disorders – even for “victims of radioactive catastrophes.”

    /news-media/in-the-news/can-the-organ-of-life-save-lives